Sabutoclax

Sabutoclax is a potent and effective Bcl-2 Family (Bcl-2, Bcl-XL, Mcl-1, Bfl-1) inhibitor with IC50s of 0.32 μM, 0.31 μM, 0.20 μM, and 0.62 μM, respectively. Sabutoclax increases Bax, Bim, PUMA and survivin expression[1][2].

Product Specifications

CAS Number

[1228108-65-3]

Product Name Alternative

BI-97C1

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Bcl-2 Family

Type

Reference compound

Related Pathways

Apoptosis

Applications

Neuroscience-Neurodegeneration

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Sabutoclax.html

Purity

99.80

Solubility

DMSO : 36.67 mg/mL (ultrasonic)

Smiles

O=C(C1=C(O)C(O)=CC2=C(O)[C@@]([C@@]3=C(C)C=C4C(C(NC[C@@H](C5=CC=CC=C5)C)=O)=C(O)C(O)=CC4=C3O)=C(C)C=C12)NC[C@@H](C6=CC=CC=C6)C

Molecular Formula

C42H40N2O8

Molecular Weight

700.78

Precautions

H302, H315, H319, H335

References & Citations

[1]Wei J , et al. BI-97C1, an optically pure Apogossypol derivative as pan-active inhibitor of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. J Med Chem. 2010 May 27; 53 (10) :4166-76.|[2]Yunhui Hu, et Al. Sabutoclax, pan-active BCL-2 protein family antagonist, overcomes drug resistance and eliminates cancer stem cells in breast cancer. Cancer Lett. 2018 Jun 1:423:47-59.